The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > REGULATORY
REGULATORY
- Ferring Japan Faces Biz Improvement Order for GMP Violation at Overseas Site
May 1, 2023
- Japan Approves Mefeego as First Abortion Pill
May 1, 2023
- LDP League Calls for Generic Market Entry Rules to Ensure Supply: Draft Proposal
April 28, 2023
- Outline of Expert Panel Report Calls for New Forum to Discuss Generics’ Future, Revisiting of Spillover Rule
April 28, 2023
- Lawmakers’ League on Pollen Allergy Boosts Up
April 27, 2023
- As Japan Mulls Pushing Back Fee Revisions, Chuikyo Reps Fret Impact on Drug Price Updates
April 27, 2023
- Shionogi CEO Presses Govt for G7 Debate on Pull Incentives for Antibiotics
April 27, 2023
- Mpox Cases Hit 120 in Japan: MHLW
April 27, 2023
- Chuikyo OKs CEA Discussion Timeline for FY2024 Reform; Industry Hearing Set for August, November
April 27, 2023
- Ultomiris Clears Japan Panel Review for NMOSD Approval
April 27, 2023
- Japan Panel to Draw Up Revision Outline for Basic Blood Products Policy by September, Eyes Profitability Improvement
April 26, 2023
- Skyrizi in Line for Palmoplantar Pustulosis Nod, Vanflyta for 1st Line AML
April 25, 2023
- Shelf Life for Lagevrio Extended to 36 Months in Japan
April 24, 2023
- MHLW Panel OKs 192 More Health Damage Claims for COVID-19 Vaccines
April 24, 2023
- Japan’s Diet Enacts Bill to Establish Pandemic Response Agency
April 24, 2023
- Health Ministry Panel OKs Japan’s First Abortion Pill with Official Go-Ahead Set for May
April 24, 2023
- Delay Reimbursement Fee Revisions by Few Months: LDP Project Team
April 21, 2023
- Health Minister Negative about Fee Premiums for Use of Japan-Made Drugs
April 20, 2023
- Japan to End Priority Review for COVID Drugs and Vaccines after Severity Downgrade: Official
April 20, 2023
- Industry Groups Call for Reimbursement Scheme Tailored to Characteristics of SaMDs
April 19, 2023
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…